Introduction:

Endoscopic nasal surgery was used to treat nasal disorders such as chronic sinusitis and nasal polyps. Intraoperative bleeding prolonged surgery and increased the risk of postoperative complications. Tranexamic acid, an antifibrinolytic agent, was used to reduce bleeding in various surgical procedures, although results in endoscopic nasal surgery were contradictory. This study described the effect of tranexamic acid on intraoperative bleeding in patients undergoing endoscopic nasal surgery.

Objective:

To describe the effect of tranexamic acid on intraoperative bleeding in patients undergoing endoscopic nasal surgery.

Materials and Methods:

An experimental open, controlled, non-randomized clinical trial was conducted. Adult patients of both sexes with an indication for endoscopic nasal surgery, treated at between September 2022 and March 2023, were included. The patients were divided into two groups: the "tranexamic acid" group and the "control" group. Sociodemographic, clinical, and surgical variables were analyzed.

Results:

A total of 42 subjects aged 18 to 60 years were included, with a mean age of 31.43 years. 57.1% were men. The average duration of surgery was 1.7 hours, and the average bleeding was 63.45 cc. The Boezaart bleeding grade was mostly grade 2 (50%). No significant relationship was found between the use of tranexamic acid and the duration of surgery or average bleeding.

Conclusion:

Tranexamic acid did not show a significant relationship with the duration of surgery or average bleeding in patients undergoing endoscopic nasal surgery.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )